-
Post date
March 28, 2022
-
Posted by
Kieran Robertson
-
Posted in
clinical trials shroom stocks, FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, Filament Health Trials, filament stock, Major depressive disorder, MDD, mental health, mental health issues, mushroom, mushroom formulation, mushroom growing kit, mushroom hat, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, organic mushrooms, psilocybin mushrooms, Psychedelics, shrooms, spent mushroom compost, Today's Idea
-
Post date
March 28, 2022
-
Posted by
Kieran Robertson
-
Posted in
clinical trials shroom stocks, FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, Filament Health Trials, filament stock, Major depressive disorder, MDD, mental health, mental health issues, mushroom, mushroom formulation, mushroom growing kit, mushroom hat, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, organic mushrooms, psilocybin mushrooms, Psychedelics, Series, shrooms, spent mushroom compost, Today's Idea
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
-
Post date
March 18, 2022
-
Posted by
Kieran Robertson
-
Posted in
best psychedelics companies, best psychedelics stocks, Canadian psychedelics companies, Canadian psychedelics market, clinical trials psychedelics, Dealer's License, Health Canada approval, licensed dealer, medical psychedelics, mushroom, mushroom formulation, mushroom laws, mushroom legalization, mushroom market, mushroom markets, mushroom research, mushroom stocks, Mushrooms, natural psychedelics, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin mushrooms, Psychedelics, psychedelics stocks 2022
-
Post date
April 27, 2021
-
Posted by
Lukas Kane
-
Posted in
5 best Canadian Biotechs, Biotech, Biotech collaborations, Bucillamine, Canadian Biotech, cancer treatment, Cannabis, clinical sites, Covid-19 treatment, CRO, CymaBay Therapeutics (CBAY.NASDAQ), Fabio Chianelli, Featured Content, Health Science, Institutional Review Board, Investigational new drug, IRB, Kane, liver disease, massive buying, mushroom, mushroom research, Mushrooms, Novotech, Pharm-Olam LLC, PharmaTher, PharmaTher (PHRM.C), Phase 3 FDA trial, Phase 3 trial, Psychedelics, research, resperitory viral infections, Revive Therapeutics, RVV.C, Scribes, Series, shrooms, stock price surge, undervalued bio tech companies, wealth creation